Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Labels

March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info: https://youtu.be/811v7RLXP9M
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect
rareconnect.org TMAU

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

https://www.meboblog.com/2023/01/denver-tmau-test-survey-tbc-who-it-is.html

Friday, June 29, 2012

Dr. Shephard's Presentation for the Miami Beach Meetup/Conference - Pharmacogenetics & Personalized Medicine



Presentation created for the 3rd annual MEBO Research Meetup/Conference held at Miami South Beach on the weekend of June 23, 2012 by:

Elizabeth Shephard, PhD
Professor of Molecular Biology
Vice Dean Education, Biosciences
Institute of Structural and Molecular Biology
Division of Biosciences
Darwin Building, UCL Genetics Institute
University College London
MEBO Research Scientific Advisor
Member of the MEBO Institutional Review Board


In this presentation, Dr. Shephard explains how a genetic mutation in FMO3 and/or CYP can produce a mutation in a drug metabolizing enzyme needed to clear certain drugs. As a consequence, there is very little detoxification and change in the drug, and thus, plasma concentration remains high. When taking the next dose, the same happens, resulting in the plasma concentration increasing over time without decreasing between each dose. This is potential for “adverse drug effects,” and in worst-case scenario, having too much drug, overdosing, and even death.

In addition, Dr. Shephard explains how "Many drugs are metabolized by more than one enzyme" including CYPs (P450s), and she gives us a "very short list" as examples of some FMO3 drug substrates more commonly used, including anaesthetics, a variety of anti-inflammatory (throat lozenges and sprays), anti-psychotic, and neuronal stimulant, such as nicotine. She refers to a study that has proven the inability or compromised ability of people with TMAU to be metabolize Benzydamine, as stated in a previous post in this blog.

So sufferers may ask themselves, what should we do with all this information? Should we make the decision to stop taking any or all medications prescribed by our physician, or should we take it upon ourselves to modify the dose as we see fit on our own volition? Absolutely not. This is not what MEBO Research is recommending at all. Instead, MEBO is all about raising awareness, and it begins with a discussion of these concepts with one's physician. We need to have proactive discussions with out GPs about the topics Dr. Shephard brings up in this video, such as "Pharmacogenetics" and "Personalized Medicine." But most importantly, we need to take this information that Dr. Shephard gives us one step further. We need to listen to and study our bodies and to learn to discern and identify our adverse reactions to any given medication to then communicate it with our GPs. We need to clearly identify when we note the effects of a drug is consistently and abnormally increasing in intensity - when we feel that a medication is not "metabolizing and clearing" from our system resulting in adverse effects to the drug.

Dr. Shephard also tells us,

One thing to remember is that many people have unpleasant effects from antipsychotics and antidepressants and this may not be due to changes in FMO3.




------ Ref: Dr. Shephard, 2012; note: short list. More names to come.


Benzydamine (also known as Tantum Verde [1]), available as the hydrochloride, is a locally-acting nonsteroidal anti-inflammatory drug with local anaesthetic and analgesic properties for pain relief and anti-inflammatory treatment of inflammatory conditions of the mouth and throat.[2]

Chlorpromazine: marketed in the United States as Thorazine and elsewhere as Largactil) is a typical antipsychotic

Clozapine (sold as Clozaril, Gen-Clozapine in Canada, Azaleptin, Leponex, Fazaclo, Froidir; Denzapine, Zaponex in the UK; Klozapol in Poland, Clopine in Australia and New Zealand) is an atypical antipsychotic medication used in the treatment of schizophrenia, and is also used off-label in the treatment of bipolar disorder.

Fluphenazine is a typical antipsychotic drug used for the treatment of psychoses such as schizophrenia and acute manic phases of bipolar disorder. It belongs to the piperazine class of phenothiazines.
Fluphenazine decanoate: Modecate, Prolixin Decanoate, Dapotum D, Anatensol, Fludecate, Sinqualone Deconoate
Fluphenazine enanthate: Dapotum Injektion, Flunanthate, Moditen Enanthate Injection, Sinqualone Enanthate
Fluphenazine hydrochloride: Prolixin, Permitil, Dapotum, Lyogen, Moditen, Omca, Sediten, Selecten, Sevinol, Sinqualone, Trancin

Olanzapine* (trade name Zyprexa or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.[2] Olanzapine is structurally similar to clozapine, but is classified as a thienobenzodiazepine.*

Perazine (Taxilan) is a moderate-potency typical antipsychotic of the phenothiazine class. It is quite similar to chlorpromazine, and acts as a dopamine antagonist.

(S) Nicotine, self-explanatory


*NOTE: Olanzapine is widely prescribed and is one of the top drugs of choice, as is Zyprexa, at this time. thienobenzodiazepines are being explored widely, and have been heralded as replacements for benzodiazepines due to less addiction.


Since body and/or breath malodor sufferers may have deficient FMO3 and/or CYP metabolic conditions, instead of suggesting that one shy away from taking much needed medications, including the ones mentioned on this list, it is recommended to discuss the effects one has to these drugs with the prescribing doctor in an effort to help the physician tailor the drug dose to best work with the sufferer's metabolism and clearance performance, thus practicing "Personalized Medicine."

Thanks to everyone who was a part of this presentation and this post.

María

María de la Torre
Founder and Executive Director

A Public Charity
www.meboresearch.org
www.brasil.meboresearch.org
maria.delatorre@meboresearch.org
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)



SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.


Please use your credit card to make your donation to MEBO.


Subscribe for latest posts : Enter your email address:

Delivered by FeedBurner


A EURORDIS and NORD Member Organization

0 comments:

Post a Comment